You are here

Our science / Clinical Trials / Find a Trial / NCT00195598

Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Back to Search Print Save as PDF Bookmark Trial

NCT00195598

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Jundiai, Sao Paulo, Brazil
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Panic Disorders
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3
months before study day 1.

- Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening
visit.

- Provide a written informed consent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine

- Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.

- Psychopharmacologic drugs within 14 days of study day 1

NCT00195598
Pfizer
Completed
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease
NCT02433158
All Genders
6+
Years
Multiple Sites
Diabetes Mellitus, Type 2 Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
NCT01301456
Females
18+
Years
Multiple Sites
Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 in Subjects With Hypercholesterolemia
NCT01435382
All Genders
18+
Years
Multiple Sites
Post-Traumatic Stress Disorders
A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD
NCT00150306
All Genders
6+
Years
Multiple Sites
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Panic Disorders
  • Drug: VENLAFAXINE
  • Drug: Paroxetine
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
April 2006
April 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
  • Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
  • Provide a written informed consent

Exclusion Criteria:

  • Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
  • Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
  • Psychopharmacologic drugs within 14 days of study day 1
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
 
NCT00195598
0600B-101359
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Trial Manager Pfizer CT.gov Call Center
Wyeth is now a wholly owned subsidiary of Pfizer
March 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now